Monitor Invivyd's BLA submission progress and FDA feedback over the next 12 months. The transition period mitigates immediate revenue loss, but failure to secure full approval could render the company without a marketed product. Stock price likely to reflect binary BLA outcome risk.
Price Chart
Executive Summary
Invivyd (IVVD) announced receipt of a 12-month advanced notice of EUA termination for its only authorized product, PEMGARDA (pemivibart), following HHS termination of the COVID-19 EUA declaration effective June 29, 2027. The company intends to pursue a BLA for full FDA approval and is in active dialogue with the FDA. The termination removes the product's current authorization but provides a transition period; the outcome of the BLA path is uncertain.
Key Facts
- FDA sent Notice of Termination for PEMGARDA EUA, effective June 29, 2027 (12-month transition period).
- HHS announced termination of the COVID-19 EUA declaration on June 30, 2026, effective June 29, 2027.
- Invivyd intends to submit a Biologics License Application (BLA) for full approval of PEMGARDA.
- PEMGARDA is Invivyd's only authorized product, used for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.
- Chairman Marc Elia stated belief that PEMGARDA has sufficient clinical and post-authorization data to support BLA approval.
Financial Impact
EUA termination removes current revenue stream from PEMGARDA; company's future revenue depends on BLA outcome. No financial figures provided in filing.
Risk Factors
- FDA may not approve BLA, leaving Invivyd without a marketed product after June 2027.
- Competing monoclonal antibodies or vaccines may reduce market need for PEMGARDA.
- Company may require additional capital to fund operations through BLA review.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-295539 |
| Document: ivvd-ex99_1.htm | 0001193125-26-295539 |
| Document: 0001193125-26-295539-index-headers.html | 0001193125-26-295539 |
| Document: 0001193125-26-295539-index.html | 0001193125-26-295539 |
| Document: 0001193125-26-295539.txt | 0001193125-26-295539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access